tartephedreel n - krople doustne, roztwór
biologische heilmittel heel gmbh - krople doustne, roztwór - -
husteel - krople doustne, roztwór
biologische heilmittel heel gmbh - scilla d4 + cuprum aceticum + causticum hahnemanni + belladonna + arsenum iodatum d8 - krople doustne, roztwór - -
malia kaszel - syrop
zakład farmaceutyczny "amara" sp. z o.o. - syrop - -
traumeel s - Żel
biologische heilmittel heel gmbh - Żel - -
niquitin fruit 4 mg guma do żucia, lecznicza
perrigo poland sp. z o.o. - nicotinum - guma do żucia, lecznicza - 4 mg
rivaroxaban accord
accord healthcare s.l.u. - rywaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - Środki przeciwzakrzepowe - profilaktyka żylnej choroby zakrzepowo-zatorowej (Żchzz) u dorosłych pacjentów poddawanych planowej operacji wymiany stawu biodrowego lub kolanowego. leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych. (see section 4. 4 for haemodynamically unstable pe patients. leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych. (see section 4. 4 hemodynamicznie niestabilna ТЭЛА pacjentów). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
apixaban accord
accord healthcare s.l.u. - Апиксабан - venous thromboembolism; stroke; arthroplasty - Środki przeciwzakrzepowe - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. profilaktyka udaru mózgu i zatorowości systemowej u dorosłych pacjentów z неклапанной migotaniem przedsionków (nvaf), z jednym lub więcej czynników ryzyka, takich jak udar mózgu lub przemijający atak niedokrwienny (tia); wiek ≥ 75 lat; nadciśnienie tętnicze; cukrzyca; objawowa niewydolność serca (klasa nyha ≥ drugi). leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych (patrz punkt 4. 4 hemodynamicznie niestabilna ТЭЛА pacjentów). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych (patrz punkt 4. 4 hemodynamicznie niestabilna ТЭЛА pacjentów).
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rywaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Środki przeciwzakrzepowe - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
abatixent 5 mg tabletki powlekane
sandoz gmbh - apixabanum - tabletki powlekane - 5 mg
abatixent 2,5 mg tabletki powlekane
sandoz gmbh - apixabanum - tabletki powlekane - 2,5 mg